(Q38480274)

English

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival

scientific article published on 15 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

0 references

1 reference

Europe PubMed Central

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

based on heuristic

inferred from title

Jean-Charles Soria

9

object named as

Jean-Charles Soria

0 references

Gwénaël Le Teuff

11

object named as

Gwénaël Le Teuff

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Marcos A dos Santos

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jean-Pierre Pignon

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Pierre Blanchard

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Delphine Lefeuvre

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Antonin Levy

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Mehdi Touat

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Guillaume Louvel

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Frédéric Dhermain

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Eric Deutsch

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

15 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

123

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

307-314

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Lessons learned in the development of targeted therapy for malignant gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Patients' decision-making process regarding participation in phase I oncology research

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

New concepts for phase I trials: evaluating new drugs combined with radiation therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Better reporting of harms in randomized trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Meta-analysis when only the median survival times are known: a comparison with individual patient data results

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

How should meta-regression analyses be undertaken and interpreted?

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Conducting Meta-Analyses in R with the metafor Package

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1802-5

21 January 2018

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25975195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/25975195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25975195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-015-1802-5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38480274&oldid=2201753237"